Comparison of Recurrent With First-Time In-Stent Restenosis

• Published in: The American journal of cardiology 2023-11, Vol.206, p.168-174
• Main Authors: Zhang, Han, Zhang, Yin, Tian, Tao, Wang, Tianjie, Chen, Jue, Yuan, Jinqing, Qian, Jie, Hu, Fenghuan, Dou, Kefei, Qiao, Shubin, Wu, Yongjian, Guan, Changdong, Yang, Weixian, Song, Lei
• Format: Article
• Language: English
• Subjects: Angioplasty; Body mass index; Cardiovascular disease; Cholesterol; Clinical outcomes; coronary artery disease; Coronary vessels; Diabetes; Ejection fraction; Health hazards; Health services; High density lipoprotein; Hypertension; Implants; in-stent restenosis; Kidney diseases; Lesions; Low density lipoprotein; Medical prognosis; Myocardial infarction; Patients; percutaneous coronary intervention; Rank tests; recurrent; Regression analysis; Restenosis; Statistical analysis; Stents; Stroke; Vein & artery diseases
• ISSN: 0002-9149; 1879-1913; 1879-1913
• DOI: 10.1016/j.amjcard.2023.08.131

Recurrent in-stent restenosis (Re-ISR) remains a therapeutic challenge. We aimed to investigate the clinical characteristics, treatment, and long-term outcomes in patients with Re-ISR compared with those with first-time ISR (First-ISR). This retrospective study consecutively enrolled patients who underwent percutaneous coronary intervention (PCI) for ISR in Fuwai Hospital between January 2017 and December 2018. Re-ISR was defined as a second event of ISR after a previous successful treatment of the ISR lesion. The primary outcome was defined as a composite of all-cause death, spontaneous myocardial infarction, and repeat revascularization. A total of 2,006 patients (2,154 lesions) with ISR underwent successful PCI were enrolled and categorized into 2 groups: the Re-ISR group (246 patients/259 lesions) and the First-ISR group (1,760 patients/1,895 lesions). During a mean follow-up of 36 months, the primary outcomes occurred in 80 patients (32.5%) in the Re-ISR group and 349 patients (19.3%) in the First-ISR group (p